{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:52:56Z","timestamp":1788537176847,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Does addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>At the doses investigated, the addition of CG beta reduced the number of intermediate follicles and related down-stream parameters including the number of oocytes and blastocysts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>CG beta is a novel recombinant hCG (rhCG) molecule expressed by a human cell line (PER.C6\u00ae) and has a different glycosylation profile compared to urinary hCG or rhCG derived from a Chinese Hamster Ovary (CHO) cell line. In the first-in-human trial, the CG beta pharmacokinetics were similar between men and women. In women, the AUC and the peak serum concentration (Cmax) increased approximately dose proportionally following single and multiple daily doses. In men, a single dose of CG beta provided higher exposure with a longer half-life and proportionately higher testosterone production than CHO cell-derived rhCG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This placebo-controlled, double-blind, randomized trial (RAINBOW) was conducted in five European countries to explore the efficacy and safety of CG beta as add-on treatment to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Randomization was stratified by centre and age (30\u201337 and 38\u201342\u2009years). The primary endpoint was the number of good-quality blastocysts (Grade 3 BB or higher). Subjects were randomized to receive either placebo or 1, 2, 4, 8 or 12\u2009\u00b5g CG beta added to the daily individualized follitropin delta dose during ovarian stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>In total, 620 women (30\u201342\u2009years) with anti-M\u00fcllerian hormone (AMH) levels between 5 and 35\u2009pmol\/l were randomized in equal proportions to the six treatment groups and 619 subjects started treatment. All 619 subjects were treated with an individualized dose of follitropin delta determined based on AMH (Elecsys AMH Plus Immunoassay) and body weight. Triggering with rhCG was performed when 3 follicles were \u226517\u2009mm but no more than 25 follicles \u226512\u2009mm were reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>The demographic characteristics were comparable between the six treatment groups and the overall mean age, body weight and AMH were 35.6\u2009\u00b1\u20093.3\u2009years, 65.3\u2009\u00b1\u200910.7\u2009kg and 15.3\u2009\u00b1\u20097.0\u2009pmol\/l, respectively. The incidence of cycle cancellation (range 0\u20132.9%), total follitropin delta dose (mean 112\u2009\u00b5g) and duration of stimulation (mean 10\u2009days) were similar across the groups. At stimulation Day 6, the number and size of follicles was similar between the treatment groups, whereas at the end-of-stimulation dose-related decrease of the intermediate follicles between 12 and 17\u2009mm was observed in comparison to the placebo group. In contrast, the number of follicles \u226517\u2009mm was similar between the CG beta dose groups and the placebo group. A reduced number of intermediate follicles (12 to 17\u2009mm) and fewer oocytes (mean range 9.7 to 11.2) were observed for all doses of CG beta compared to the follitropin delta only group (mean 12.5). The mean number of good-quality blastocysts was 3.3 in the follitropin delta group and ranged between 2.1 and 3.0 across the CG beta groups. The incidence of transfer cancellation was higher in the 4, 8 and 12\u2009\u00b5g group, mostly as no blastocyst was available for transfer. In the group receiving only follitropin delta, the ongoing pregnancy rate (10\u201311\u2009weeks after transfer) was 43% per started cycle versus 28\u201339% in CG beta groups and 49% per transfer versus 38\u201350% in the CG beta groups. There was no apparent effect of CG beta on the incidence of adverse events, which was 48.1% in the placebo group and 39.6\u201352.3% in the CG beta dose groups. In line with the number of collected oocytes, the overall ovarian hyperstimulation syndrome incidence remained lower following follitropin delta with CG beta (2.0\u201310.3%) compared with follitropin delta only treatment (11.5%). Regardless of the dose, CG beta was safe and well-tolerated with low risk of immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>The effect of the unique glycosylation of CG beta and its associated potency implications in women were not known prior to this trial. Further studies will be needed to evaluate optimal doses of CG beta for this and\/or different indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>The high ongoing pregnancy rate in the follitropin delta group supports the use of individualized follitropin delta dosing in a long GnRH agonist protocol. The addition of CG beta reduced the presence of intermediate follicles with the investigated doses and negatively affected all down-stream parameters. Further clinical research will be needed to assess the optimal dose of CG beta in the optimal ratio to follitropin delta to develop this novel combination product containing both FSH and LH activity for ovarian stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>The study was funded by Ferring Pharmaceuticals, Copenhagen, Denmark. B.M. and P.L. are employees of Ferring Pharmaceuticals. M.F.S., H.V., C.Y.A., M.F., C.B., A.P. and Y.K. have received institutional clinical trial fees from Ferring Pharmaceuticals. C.B. has received payments for lectures from Organon, Ferring Pharmaceuticals, Merck A\/S and Abbott. M.F.S. has received payment for lectures from Ferring Pharmaceuticals. Y.K. has received payment for lectures from Merck and travel support from Gedeon Richter. H.V. has received consulting fees from Oxo and Obseva and travel support from Gedeon Richter, Ferring Pharmaceuticals and Merck. C.Y.A. has received payment for lectures from IBSA, Switzerland. M.F and C.Y.A. were reimbursed as members of the Data Monitoring Board in this trial. M.F. has an issued patent about unitary combination of FSH and hCG (EP1633389).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>2017-003810-13 (EudraCT Number)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION DATE<\/jats:title>\n                    <jats:p>21 May 2018<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATE OF FIRST PATIENT\u2019S ENROLMENT<\/jats:title>\n                    <jats:p>13 June 2018<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deac061","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:15:09Z","timestamp":1649920509000},"page":"1161-1174","source":"Crossref","is-referenced-by-count":23,"title":["A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol"],"prefix":"10.1093","volume":"37","author":[{"given":"Manuel","family":"Fern\u00e1ndez S\u00e1nchez","sequence":"first","affiliation":[{"name":"IVI-RMA Seville , Seville, Spain"},{"name":"Departament of Surgery, Universidad de Sevilla , Seville, Spain"},{"name":"Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide , Seville, Spain"},{"name":"Fundacion IVI, Instituto Investigaci\u00f3n Sanitaria La Fe , Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Vi\u0161nov\u00e1","sequence":"additional","affiliation":[{"name":"IVF CUBE , Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Larsson","sequence":"additional","affiliation":[{"name":"Global Biometrics, Ferring Pharmaceuticals , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Yding Andersen","sequence":"additional","affiliation":[{"name":"Laboratory of Reproductive Biology, Copenhagen University Hospital and Faculty of Health Science, Copenhagen University , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filicori","sequence":"additional","affiliation":[{"name":"GynePro Medical Group , Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-5158","authenticated-orcid":false,"given":"Christophe","family":"Blockeel","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-104X","authenticated-orcid":false,"given":"Anja","family":"Pinborg","sequence":"additional","affiliation":[{"name":"Fertility Clinic, Rigshospitalet, Copenhagen University Hospital , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacoub","family":"Khalaf","sequence":"additional","affiliation":[{"name":"Assisted Conception Unit, Guy\u2019s Hospital , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-8013","authenticated-orcid":false,"given":"Bernadette","family":"Mannaerts","sequence":"additional","affiliation":[{"name":"Reproductive Medicine & Maternal Health, Ferring Pharmaceuticals , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Rainbow Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blockeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"de Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Vi\u0161nov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Uher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan Mrazek","family":"GYNEM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Sobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina La Cour","family":"Freiesleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-104X","authenticated-orcid":false,"given":"Anja","family":"Pinborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Husth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Bentin-Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Fern\u00e1ndez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio Garcia","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Verdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Narvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Drakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacoub","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"2022060105580510600_deac061-B1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1472-6483(10)61059-0","article-title":"Gonadotrophin-releasing hormone antagonist for assisted conception: a cochrane review","volume":"14","author":"Al-Inany","year":"2007","journal-title":"Reprod Biomed Online"},{"key":"2022060105580510600_deac061-B2","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting","volume":"26","year":"2011","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B3","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09513590.2012.705379","article-title":"Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations","volume":"29","author":"Arce","year":"2013","journal-title":"Gyn Endocrinol"},{"key":"2022060105580510600_deac061-B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/edrv.23.2.0462","article-title":"The lutropin\/choriogonadotropin receptor, a 2002 perspective","volume":"23","author":"Ascoli","year":"2002","journal-title":"Endocr Rev"},{"key":"2022060105580510600_deac061-B6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/rmb2.12066","article-title":"Single-dose pharmacokinetic study comparing the pharmacokinetics of recombinant human chorionic gonadotropin in healthy Japanese and Caucasian women and recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin in healthy Japanese women","volume":"17","author":"Bagchus","year":"2017","journal-title":"Reprod Med Biol"},{"key":"2022060105580510600_deac061-B7","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/cts.13037","article-title":"First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age","volume":"14","author":"Broks\u00f8 Kyhl","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2022060105580510600_deac061-B8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1210\/er.2018-00065","article-title":"Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG","volume":"39","author":"Casarini","year":"2018","journal-title":"Endocr Rev"},{"key":"2022060105580510600_deac061-B9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-7827-7-8","article-title":"New discoveries on the biology and detection of human chorionic gonadotropin","volume":"7","author":"Cole","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"2022060105580510600_deac061-B10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7827-8-102","article-title":"Biological functions of hCG and hCG-related molecules","volume":"8","author":"Cole","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"key":"2022060105580510600_deac061-B11","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1016\/S0021-9258(17)32914-9","article-title":"Gonadotropin induced loss of hormone receptors and desensitization of adenylate cyclase in the ovary","volume":"251","author":"Conti","year":"1976","journal-title":"J Biol Chem"},{"key":"2022060105580510600_deac061-B12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0015-0282(98)00332-X","article-title":"Timed analysis of the nuclear maturation of oocytes in early preantral mouse follicle culture supplemented with recombinant gonadotropin","volume":"70","author":"Cortvrindt","year":"1998","journal-title":"Fert Steril"},{"key":"2022060105580510600_deac061-B13","author":"Cottingham","year":"2011"},{"key":"2022060105580510600_deac061-B14","year":"2017"},{"key":"2022060105580510600_deac061-B15","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","article-title":"Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicenter trial","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles","volume":"38","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2022060105580510600_deac061-B17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.fertnstert.2005.02.036","article-title":"Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation","volume":"84","author":"Filicori","year":"2005","journal-title":"Fert Steril"},{"key":"2022060105580510600_deac061-B18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1210\/jcem.87.3.8322","article-title":"Stimulation and growth of antral follicles by selective LH activity administration in women","volume":"87","author":"Filicori","year":"2002","journal-title":"J Clin Endocrinol. Metab"},{"key":"2022060105580510600_deac061-B19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1210\/jcem.86.1.7108","article-title":"Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation","volume":"86","author":"Filicori","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060105580510600_deac061-B20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fendo.2018.00452","article-title":"Androgen action in the ovary","volume":"9","author":"Franks","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022060105580510600_deac061-B21","first-page":"378","volume-title":"Towards Reproductive Certainty. The Plenary Proceedings of the 11th World Congress on in Vitro Fertilization and Human Reproductive Genetics","author":"Gardner","year":"1999"},{"key":"2022060105580510600_deac061-B22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"2022060105580510600_deac061-B23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0950-3552(97)80036-3","article-title":"Role of androgens in follicle maturation and atresia","volume":"11","author":"Hillier","year":"1997","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"2022060105580510600_deac061-B24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/humrep\/deh682","article-title":"Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study","volume":"20","author":"Hugues","year":"2005","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1210\/jc.2012-1427","article-title":"LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles","volume":"97","author":"Jeppesen","year":"2012","journal-title":"J Clin Endorinol Metab"},{"key":"2022060105580510600_deac061-B26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EC-17-0067","article-title":"Comparative pharmacology of a new recombinant FSH expressed by a human cell line","volume":"6","author":"Koechling","year":"2017","journal-title":"Endocr Connect"},{"key":"2022060105580510600_deac061-B27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/humrep\/deg066","article-title":"Clinical evidence for an LH \u2018ceiling\u2019 effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation","volume":"18","author":"Loumaye","year":"2003","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1095\/biolreprod51.1.72","article-title":"Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormone","volume":"51","author":"Mannaerts","year":"1994","journal-title":"Biol Reprod"},{"key":"2022060105580510600_deac061-B29","first-page":"200","article-title":"Initial and cyclic recruitment of ovarian follicles","volume":"21","author":"McGee","year":"2000","journal-title":"Endocr Rev"},{"key":"2022060105580510600_deac061-B30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mce.2012.01.021","article-title":"Structure, function and regulation of gonadotropin receptors\u2014a perspective","volume":"356","author":"Menon","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2022060105580510600_deac061-B31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1095\/biolreprod.103.024471","article-title":"Regulation of luteinizing hormone\/human chorionic gonadotropin receptor expression: a perspective","volume":"70","author":"Menon","year":"2004","journal-title":"Biol Reprod"},{"key":"2022060105580510600_deac061-B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"2022060105580510600_deac061-B33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.bi.50.070181.002341","article-title":"Glycoprotein hormones: structure and function","volume":"50","author":"Pierce","year":"1981","journal-title":"Annu Rev Biochem"},{"key":"2022060105580510600_deac061-B34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"8","author":"Shankar","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"2022060105580510600_deac061-B35","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1093\/humrep\/des256","article-title":"A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization","volume":"27","author":"Thuesen","year":"2012","journal-title":"Hum Reprod"},{"key":"2022060105580510600_deac061-B36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/cen.12186","article-title":"Endocrine effects of hCG supplementation to recombinant FSH throughout controlled ovarian stimulation for IVF: a dose-response study","volume":"79","author":"Thuesen","year":"2013","journal-title":"Clin Endocrinol"},{"key":"2022060105580510600_deac061-B37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1472-6483(10)61927-X","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers","volume":"4","author":"Trinchard-Lugan","year":"2002","journal-title":"Reprod Biomed Online"},{"key":"2022060105580510600_deac061-B38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1023\/A:1020569508927","article-title":"Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation","volume":"16","author":"Yding Andersen","year":"1999","journal-title":"J Ass Reprod Genet"},{"key":"2022060105580510600_deac061-B39","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/humrep\/dem221","article-title":"Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF","volume":"22","author":"Ziebe","year":"2007","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/6\/1161\/43890003\/deac061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/6\/1161\/43890003\/deac061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:29:36Z","timestamp":1700422176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/6\/1161\/6572208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deac061","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,22]]}}}